Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey.

Fiorentino M, Sagaon-Teyssier L, Ndiaye K, Suzan-Monti M, Mengue MT, Vidal L, Kuaban C, March L, Laurent C, Spire B, Boyer S; EVOLCam Study Group.

Womens Health (Lond). 2019 Jan-Dec;15:1745506519848546. doi: 10.1177/1745506519848546.

PMID:
31177929
2.

Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention.

Puppo C, Mabire X, Cotte L, Castro DR, Spire B, Cua E, Pialoux G, Monti MS, Pasquet A, Raffi F, Molina JM, Préau M; ANRS-Ipergay Study Group.

AIDS Educ Prev. 2019 Jun;31(3):259-272. doi: 10.1521/aeap.2019.31.3.259.

PMID:
31145006
3.

A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey.

Sagaon-Teyssier L, Vilotitch A, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 study group.

BMC Public Health. 2019 May 17;19(1):590. doi: 10.1186/s12889-019-6905-z.

4.

Male clients of male sex workers in West Africa: A neglected high-risk population.

Kounta CH, Sagaon-Teyssier L, Coulaud PJ, Mora M, Maradan G, Bourrelly M, Keita AA, Yoro SB, Anoma C, Coulibaly C, Dah ETT, Agbomadji S, Mensah E, Bernier A, Couderc C, Dembélé Keita B, Laurent C, Spire B; CohMSM Study Group.

PLoS One. 2019 May 1;14(5):e0212245. doi: 10.1371/journal.pone.0212245. eCollection 2019.

5.

Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).

Garay OU, Nishimwe ML, Bousmah MA, Janah A, Girard PM, Chêne G, Moinot L, Sagaon-Teyssier L, Meynard JL, Spire B, Boyer S.

Pharmacoecon Open. 2019 Apr 9. doi: 10.1007/s41669-019-0130-7. [Epub ahead of print]

6.

Taking empowerment into account: the response of community-based organisations to the HIV care needs of men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).

Coulaud PJ, Préau M, Maradan G, Mora M, Traoré F, Oga M, Thio E, Ekon L, Dembele Keita B, Anoma C, Ter Tiero Dah E, Mensah E, Bernier A, Couderc C, Laurent C, Spire B; CohMSM Study Group.

AIDS Care. 2019 Mar 4:1-9. doi: 10.1080/09540121.2019.1587358. [Epub ahead of print]

PMID:
30829534
7.

Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation.

Mabire X, Puppo C, Morel S, Mora M, Rojas Castro D, Chas J, Cua E, Pintado C, Suzan-Monti M, Spire B, Molina JM, Préau M.

Am J Mens Health. 2019 Jan-Feb;13(1):1557988319827396. doi: 10.1177/1557988319827396.

8.

Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study.

Kankou JM, Bouchaud O, Lele N, Guiguet M, Spire B, Carrieri MP, Abgrall S; ANRS-VIHVO Study Group.

J Immigr Minor Health. 2019 Feb 22. doi: 10.1007/s10903-019-00864-y. [Epub ahead of print]

PMID:
30796681
9.

Behavioral cardiovascular risk factors in HIV-infected people in France: Diversity of profiles across groups requires an urgent and tailored preventive approach.

Tron L, Lert F, Spire B, Dray-Spira R; ANRS-Vespa2 Study Group.

Rev Epidemiol Sante Publique. 2019 Feb;67(1):21-31. doi: 10.1016/j.respe.2018.10.006. Epub 2018 Nov 26.

PMID:
30497905
10.

Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).

Liégeois F, Eymard-Duvernay S, Boyer S, Maradan G, Kouanfack C, Domyeum J, Boyer V, Mpoudi-Ngolé E, Spire B, Delaporte E, Vidal L, Kuaban C, Laurent C; EVOLCAM study group.

HIV Med. 2019 Jan;20(1):38-46. doi: 10.1111/hiv.12681. Epub 2018 Oct 25.

PMID:
30362279
11.

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844.

PMID:
30234665
12.

Is on-Demand HIV Pre-exposure Prophylaxis a Suitable Tool for Men Who Have Sex With Men Who Practice Chemsex? Results From a Substudy of the ANRS-IPERGAY Trial.

Roux P, Fressard L, Suzan-Monti M, Chas J, Sagaon-Teyssier L, Capitant C, Meyer L, Tremblay C, Rojas-Castro D, Pialoux G, Molina JM, Spire B.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):e69-e75. doi: 10.1097/QAI.0000000000001781.

PMID:
30212434
13.

Does Quality of Life and Sexual Quality of Life in HIV Patients Differ Between Non-treated HIV Controllers and Treated Patients in the French ANRS VESPA 2 National Survey?

Préau M, Mora M, Puppo C, Laguette V, Sagaon-Teyssier L, Boufassa F, Meyer L, Lambotte O, Spire B.

AIDS Behav. 2019 Jan;23(1):132-139. doi: 10.1007/s10461-018-2237-8.

PMID:
30073634
14.

Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).

Coulaud PJ, Sagaon-Teyssier L, M'madi Mrenda B, Maradan G, Mora M, Bourrelly M, Dembélé Keita B, Keita AA, Anoma C, Babo Yoro SA, Dah TTE, Coulibaly C, Mensah E, Agbomadji S, Bernier A, Couderc C, Laurent C, Spire B; CohMSM Study Group.

Trop Med Int Health. 2018 Oct;23(10):1084-1091. doi: 10.1111/tmi.13129. Epub 2018 Aug 29.

PMID:
30055043
15.

Tackling global health inequities in the HIV response.

Makofane K, Spire B, Mtetwa P.

Lancet. 2018 Jul 28;392(10144):263-264. doi: 10.1016/S0140-6736(18)31441-7. Epub 2018 Jul 20. No abstract available.

PMID:
30032980
16.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C.

Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Review. No abstract available.

17.

What will it really take to end the HIV epidemic?

Skeen S, Prince B, van Rooyen H, Tomlinson M, Swartz A, Colvin CJ, Cooper D, Cluver L, Davidovich U, Harding R, Spire B, Catalan J, Hedge B, Sherr L.

AIDS Care. 2018 Jun;30(sup2):1-4. doi: 10.1080/09540121.2018.1488034. No abstract available.

PMID:
30012008
18.

Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.

Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Jul 5;13(7):e0199874. doi: 10.1371/journal.pone.0199874. eCollection 2018.

19.

Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPage study.

Rivierez I, Quatremere G, Spire B, Ghosn J, Rojas Castro D.

AIDS Care. 2018 Jun;30(sup2):48-53. doi: 10.1080/09540121.2018.1468014. Epub 2018 May 30.

PMID:
29848005
20.

The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship.

Di Ciaccio M, Protiere C, Rojas Castro D, Suzan-Monti M, Chas J, Cotte L, Siguier M, Cua E, Spire B, Molina JM, Preau M; ANRS IPERGAY Study Group.

AIDS Care. 2018 Jun;30(sup2):41-47. doi: 10.1080/09540121.2018.1468013. Epub 2018 May 30.

PMID:
29848004
21.

Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.

Ségéral O, Nerrienet E, Neth S, Spire B, Khol V, Ferradini L, Sarun S, Mom C, Ngin S, Charpentier C, Men P, Mora M, Mean Chhi V, Ly P, Saphonn V.

Front Public Health. 2018 Mar 19;6:63. doi: 10.3389/fpubh.2018.00063. eCollection 2018.

22.

Posttraumatic Stress Disorder as a Significant Correlate of Voluntary Antiretroviral Treatment Interruption in Adult HIV-Infected Patients Followed up in French Hospitals: Data From the ANRS-VESPA2 National Survey.

Roux P, Marcellin F, Ndiaye K, Suzan-Monti M, Mayet A, Duracinsky M, Briand-Madrid L, Maradan G, Mora M, Préau M, Verger P, Carrieri P, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Clin Psychiatry. 2018 May/Jun;79(3). pii: 17m11659. doi: 10.4088/JCP.17m11659.

PMID:
29659208
23.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).

Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group .

J Antimicrob Chemother. 2018 Jun 1;73(6):1672-1676. doi: 10.1093/jac/dky055.

PMID:
29584910
24.

Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey).

Suzan-Monti M, Celse M, Vilotitch A, Demoulin B, Dray-Spira R, Yéni P, Lert F, Spire B; ANRS VESPA2 study group.

AIDS Behav. 2018 Oct;22(10):3264-3272. doi: 10.1007/s10461-018-2077-6.

PMID:
29512033
25.

Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial.

Suzan-Monti M, Cotte L, Fressard L, Cua E, Capitant C, Meyer L, Pialoux G, Molina JM, Spire B; ANRS IPERGAY Study Group.

Sex Transm Infect. 2018 Nov;94(7):490-493. doi: 10.1136/sextrans-2017-053304. Epub 2018 Jan 29.

PMID:
29378903
26.

Renunciation of health care by people living with HIV in France is still associated with discrimination in health-care services and social insecurity - results from the ANRS-VESPA2 survey.

Fiorentino M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

Antivir Ther. 2018;23(5):443-450. doi: 10.3851/IMP3220.

PMID:
29360097
27.

Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC).

Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, Lelievre JD, Raffi F, Spire B, Lambotte O, Suzan-Monti M.

AIDS Care. 2018 Jul;30(7):914-920. doi: 10.1080/09540121.2018.1426825. Epub 2018 Jan 18.

PMID:
29347826
28.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G; ANRS 144 Inter-ACTIV study group.

Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9.

PMID:
29329763
29.

Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supply-related factors (ANRS-12288 EVOLCam survey).

Tong C, Suzan-Monti M, Sagaon-Teyssier L, Mimi M, Laurent C, Maradan G, Mengue MT, Spire B, Kuaban C, Vidal L, Boyer S; EVOL Cam group.

Trop Med Int Health. 2018 Mar;23(3):315-326. doi: 10.1111/tmi.13030. Epub 2018 Feb 2.

30.

Intimate ties of people living with HIV in France resulted both from social status and the experience of being HIV-infected: results from the ANRS-Vespa2 study, France.

Feuillet P, Hamelin C, Spire B, Dray-Spira R, Lert F; ANRS-Vespa2 study group.

AIDS Care. 2018 Jul;30(7):807-816. doi: 10.1080/09540121.2017.1420136. Epub 2017 Dec 28.

PMID:
29284284
31.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.

PMID:
29229440
32.

Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.

Durand-Zaleski I, Mutuon P, Charreau I, Tremblay C, Rojas D, Pialoux G, Chidiac C, Capitant C, Spire B, Cotte L, Chas J, Meyer L, Molina JM; ANRS IPERGAY Study Group.

AIDS. 2018 Jan 2;32(1):95-102. doi: 10.1097/QAD.0000000000001658.

PMID:
29210777
33.

Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.

Roux P, Rojas Castro D, Ndiaye K, Briand Madrid L, Laporte V, Mora M, Maradan G, Morel S, Spire B, Carrieri P.

Subst Abuse Treat Prev Policy. 2017 Nov 2;12(1):46. doi: 10.1186/s13011-017-0131-4.

34.

Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).

Protière C, Spire B, Mora M, Poizot-Martin I, Préau M, Doumergue M, Morlat P, Zucman D, Goujard C, Raffi F, Lambotte O, Suzan-Monti M.

PLoS One. 2017 Nov 2;12(11):e0187489. doi: 10.1371/journal.pone.0187489. eCollection 2017.

35.

Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Spire B, Raffi F, Lebouché B.

Qual Life Res. 2018 Feb;27(2):379-388. doi: 10.1007/s11136-017-1711-5. Epub 2017 Oct 13.

PMID:
29027607
36.

Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).

Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Viral Hepat. 2018 Feb;25(2):171-179. doi: 10.1111/jvh.12797. Epub 2017 Nov 20.

PMID:
28984055
37.

Levels and determinants of breast and cervical cancer screening uptake in HIV-infected women compared with the general population in France.

Tron L, Lert F, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)‐Vespa2 Study Group.

HIV Med. 2017 Mar;18(3):181-195. doi: 10.1111/hiv.12412. Epub 2016 Jul 6.

38.

Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21.

PMID:
28942916
39.

Adherence to PI-based 2nd-line regimens in Cambodia is not simply a question of individual behaviour: the ANRS 12276 2PICAM study.

Sagaon-Teyssier L, Mmadi Mrenda B, Khol V, Ferradini L, Mam S, Ngin S, Mora M, Maradan G, Vun Mean C, Ségéral O, Nerrienet E, Saphonn V, Spire B.

Trop Med Int Health. 2017 Nov;22(11):1428-1435. doi: 10.1111/tmi.12975. Epub 2017 Oct 2.

40.

Prevalence of HIV at the Kokoyo informal gold mining site: what lies behind the glitter of gold with regard to HIV epidemics in Mali? A community-based approach (the ANRS-12339 Sanu Gundo cross-sectional survey).

Sagaon-Teyssier L, Balique H, Diallo F, Kalampalikis N, Mora M, Bourrelly M, Suzan-Monti M, Spire B, Dembélé Keita B.

BMJ Open. 2017 Aug 3;7(8):e016558. doi: 10.1136/bmjopen-2017-016558.

41.

Patient profiles as organizing HIV clinicians' ART adherence management: a qualitative analysis.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Raffi F, Spire B, Lebouché B.

AIDS Care. 2018 Feb;30(2):207-210. doi: 10.1080/09540121.2017.1360995. Epub 2017 Aug 1.

PMID:
28764563
42.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.

PMID:
28747274
43.

Importance of the patient-physician interaction in assessing acceptability of HIV cure trials.

Protière C, Préau M, Carrieri P, Lambotte O, Spire B, Suzan-Monti M.

HIV Med. 2018 Apr;19(4):e56-e57. doi: 10.1111/hiv.12526. Epub 2017 Jun 20. No abstract available.

PMID:
28631883
44.

Is PrEP Needed for MSM in West Africa? HIV Incidence in a Prospective Multicountry Cohort.

Couderc C, Dembélé Keita B, Anoma C, Wade AS, Coulibaly A, Ehouman S, Diop AK, Yomb Y, Henry E, Spire B, Laurent C.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):e80-e82. doi: 10.1097/QAI.0000000000001288. No abstract available.

PMID:
28617734
45.

Will CURE trials introduce an uncomfortable revolution in the field of HIV research?

Protière C, Préau M, Doumergue M, Mora M, Lambotte O, Spire B, Suzan-Monti M.

HIV Clin Trials. 2017 Jul;18(4):174-175. doi: 10.1080/15284336.2017.1331603. Epub 2017 Jun 6. No abstract available.

PMID:
28587569
46.

Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial).

Nordmann S, Vilotitch A, Lions C, Michel L, Mora M, Spire B, Maradan G, Bendiane MK, Morel A, Roux P, Carrieri P; ANRS Methaville study group.

PLoS One. 2017 May 17;12(5):e0176288. doi: 10.1371/journal.pone.0176288. eCollection 2017.

47.

Self-Reported Bothersome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey.

Boyer V, Vilotitch A, Marcellin F, Demoulin B, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Pain Symptom Manage. 2017 Jul;54(1):110-119. doi: 10.1016/j.jpainsymman.2017.03.010. Epub 2017 May 4.

PMID:
28479413
48.

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.

Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boué F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6.

PMID:
28430385
49.

Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).

Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883.

PMID:
28418984
50.

Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).

Carrieri MP, Marcellin F, Fressard L, Préau M, Sagaon-Teyssier L, Suzan-Monti M, Guagliardo V, Mora M, Roux P, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

PLoS One. 2017 Feb 13;12(2):e0171645. doi: 10.1371/journal.pone.0171645. eCollection 2017.

Supplemental Content

Support Center